Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). from lead optimization to clinical proof-of-concept in asthma and allergic rhinitis

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 2915-2931

  Pettipher, Roy ^a   Whittaker, Mark ^b  

^a Oxagen Ltd   (United Kingdom)

^b EVOTEC UK LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 AZAINDOLE; ADC 3680; AM 211; AM 461; ARRY 502; AZD 1981; AZD 5985; BI 67800; CARBOXYLIC ACID; CETIRIZINE; CHEMOATTRACTANT; CHEMOATTRACTANT RECEPTOR HOMOLOGOUS MOLECULE EXPRESSED ON TH2 CELL; CYCLIC AMP; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN E; INDOLE DERIVATIVE; INDOLEACETIC ACID DERIVATIVE; MK 7246; OC 000459; PHENOXYACETIC ACID; PHENYLACETIC ACID; PROSTAGLANDIN D2; PYRAZOLE DERIVATIVE; QAV 680; RAMATROBAN; RG 1785; SETIPIPRANT; THIAZOLE DERIVATIVE; TM 27632; UNCLASSIFIED DRUG; VIDUPIPRANT;

ALLERGIC RHINITIS; ASTHMA; BINDING AFFINITY; BRONCHODILATATION; CELL SHAPE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; EOSINOPHIL; HUMAN; LYMPHOCYTE; NONHUMAN; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; VASODILATATION;

ACETIC ACIDS; ANIMALS; ASTHMA; AZA COMPOUNDS; CARBAZOLES; CLINICAL TRIALS AS TOPIC; HUMANS; INDOLEACETIC ACIDS; PYRAZOLES; PYRIMIDINES; PYRROLES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; SULFONAMIDES; TH2 CELLS; THIAZOLES;

EID: 84859787191     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2013997     Document Type: Review

References (118)

1. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2 J. Exp. Med. 2001, 193, 255-261
2. 2 receptors DP1 and CRTH2 as an approach to treat allergic diseases Nat. Rev. Drug Discovery. 2007, 6, 313-325
3. Ulven, T.; Kostenis, E. Novel CRTH2 antagonists: A review of patents from 2006 to 2009 Expert Opin. Ther. Pat. 2010, 20, 1505-1530
4. 2 receptor antagonists in development Expert Opin. Invest. Drugs 2010, 19, 947-961
5. Chen, J. J.; Budelsky, A. L. Prostaglandin D receptor CRTH2 antagonists for the treatment of inflammatory diseases Prog. Med. Chem. 2011, 50, 49-107
6. Nagata, K.; Tanaka, K.; Ogawa, K.; Kemmotsu, K.; Imai, T.; Yoshie, O.; Abe, H.; Tada, K.; Nakamura, M.; Sugamura, K.; Takano, S. Selective expression of a novel surface molecule by human Th2 cells in vivo J. Immunol. 1999, 162, 1278-1286
7. Gyles, S. L.; Xue, L.; Townsend, E. R.; Wettey, F.; Pettipher, R. A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell supernatants Immunology 2006, 119, 362-368
8. Xue, L.; Barrow, A.; Pettipher, R. Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells Clin. Exp. Immunol. 2009, 156, 126-133
9. 2 released from IgE/anti-IgE treated nasal polyp tissue Allergy 2009, 65, 304-310
10. 2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor J. Immunol. 2006, 177, 2621-2629
11. Nomiya, R.; Okano, M.; Fujiwara, T.; Maeda, M.; Kimura, Y.; Kino, K.; Yokoyama, M.; Hirai, H.; Nagata, K.; Hara, T.; Nishizaki, K.; Nakamura, M. CRTH2 plays an essential role in the pathophysiology of Cry j 1-induced pollinosis in mice J. Immunol. 2008, 180, 5680-5688
12. 2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation Respir. Res. 2007, 8, 16
13. Lukacs, N. W.; Berlin, A. A.; Franz-Bacon, K.; Sasik, R.; Sprague, L. J.; Ly, T. W.; Hardiman, G.; Boehme, S. A.; Bacon, K. B. CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation Am. J. Physiol. Lung Cell Mol. Physiol. 2008, 295, L767-L779
14. 1 and CRTH2 in promoting allergic responses Br. J. Pharmacol. 2008, 153 (Suppl 1) S191-S199
15. Xue, L.; Barrow, A.; Pettipher, R. Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway J. Immunol. 2009, 182, 7580-7586
16. Barnes, N.; Pavord, I.; Chuchalin, A.; Bell, J.; Hunter, M.; Lewis, T.; Parker, D.; Payton, M.; Collins, L. P.; Pettipher, R.; Steiner, J.; Perkins, C. M. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma Clin. Exp. Allergy 2012, 42, 38-48
17. Ulven, T.; Kostenis, E. Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist J. Med. Chem. 2005, 48, 897-900
18. 2 receptor antagonism. PCT Int. Appl. WO2003097598, 2003.
19. 2 receptor CRTH2 Bioorg. Med. Chem. Lett. 2007, 17, 5924-5927
20. Wang, Z. (Merck) Indole derivatives as CRTH2 receptor antagonists. PCT Int. Appl. WO2007019675, 2007.
21. 2 with efficacy in a murine model of allergic rhinitis Bioorg. Med. Chem. Lett. 2009, 19, 4647-4651
22. Gervais, F. G.; Sawyer, N.; Stocco, R.; Hamel, M.; Krawczyk, C.; Sillaots, S.; Denis, D.; Wong, E.; Wang, Z.; Gallant, M.; Abraham, W. M.; Slipetz, D.; Crackower, M. A.; O'Neill, G. P. Pharmacological characterization of MK-7246, a potent and selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells) antagonist Mol. Pharmacol. 2011, 79, 69-76
23. Gallant, M.; Beaulieu, C.; Berthelette, C.; Colucci, J.; Crackower, M. A.; Dalton, C.; Denis, D.; Ducharme, Y.; Friesen, R. W.; Guay, D.; Gervais, F. G.; Hamel, M.; Houle, R.; Krawczyk, C. M.; Kosjek, B.; Lau, S.; Leblanc, Y.; Lee, E. E.; Levesque, J. F.; Mellon, C.; Molinaro, C.; Mullet, W.; O'Neill, G. P.; O'Shea, P.; Sawyer, N.; Sillaots, S.; Simard, D.; Slipetz, D.; Stocco, R.; Sorensen, D.; Truong, V. L.; Wong, E.; Wu, J.; Zaghdane, H.; Wang, Z. Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases Bioorg. Med. Chem. Lett. 2011, 21, 288-293
24. Koay, N.; Tonelli, D. L.; Truong, V. L. Practical and efficient synthesis of N-fused tricyclic indoles Tetrahedron Lett. 2011, 52, 122-124
25. Zaghdane, H.; Boyd, M.; Colucci, J.; Simard, D.; Berthelette, C.; Leblanc, Y.; Wang, Z.; Houle, R.; Lévesque, J. F.; Molinaro, C.; Hamel, M.; Stocco, R.; Sawyer, N.; Sillaots, S.; Gervais, F.; Gallant, M. New indole amide derivatives as potent CRTH2 receptor antagonists Bioorg. Med. Chem. Lett. 2011, 21, 3471-3474
26. 2 receptor 1 antagonists: Impacts of glutathione trapping and glucuronide conjugation on covalent binding Bioorg. Med. Chem. Lett. 2007, 17, 3038-3043
27. Simard, D.; Leblanc, Y.; Berthelette, C.; Zaghdane, M. H.; Molinaro, C.; Wang, Z.; Gallant, M.; Lau, S.; Thao, T.; Hamel, M.; Stocco, R.; Sawyer, N.; Sillaots, S.; Gervais, F.; Houle, R.; Lévesque, J. F. Azaindoles as potent CRTH2 receptor antagonists Bioorg. Med. Chem. Lett. 2011, 21, 841-845
28. Fretz, H.; Fecher, A.; Hilpert, K.; Riederer, M. (Actelion) Tetrahydropyridoindole derivatives. PCT Int. Appl. WO2005095397, 2005.
29. Fecher, A.; Fretz, H.; Riederer, M. (Actelion) 2,3,4,9- Tetrahydrocarbazole derivatives as CRTH2 receptor antagonists. PCT Int. Appl. WO2006070325, 2006.
30. Fretz, H.; Fecher, A.; Pothier, J.; Risch, P. (Actelion) 3-Amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl)acetic acid derivatives. PCT Int. Appl. WO2008017989, 2008.
31. 2 receptor, CRTH2 J. Immunol. 2002, 168, 981-985
32. 2 receptor, CRTH2 Br. J. Pharmacol. 2002, 137, 1163-1172
33. 2 is a potent and selective CRTH2 receptor agonist and causes activation of human eosinophils and Th2 lymphocytes Prostaglandins Other Lipid Mediat. 2005, 75, 153-167
34. 2. US Appl. US2002/0022218, 2002.
35. 2 receptor CRTH2 J. Med. Chem. 2005, 48, 6174-6177
36. Frimurer, T. M.; Ulven, T.; Elling, C. E.; Gerlach, L.-O.; Kostenis, E.; HoIgberg, T. A physiocogenetic method to assign ligand-binding relationships between 7TM receptors Bioorg. Med. Chem. Lett. 2005, 15, 3707-3712
37. 2) receptor antagonists Bioorg. Med. Chem. Lett. 2006, 16, 4287-4290
38. Papaioannou, N.; Marathias, V.; Wan, Z.-K.; Kaila, N.; Ali, Z.; Saiah, E. N-Arylation of a hindered indoline as a route to 2-(2-methyl-1-(4-oxo-3,4- dihydrophthalazin-1-yl)-1H-indol-3-yl)acetic acid derivatives Tetrahedron Lett. 2011, 52, 6317-6320
39. Middlemiss, D.; Ashton, M. R.; Boyd, E. A.; Brookfield, F. A.; Pettipher, E. R. (Oxagen) Use of CRTH2 antagonist compounds in therapy. PCT Int. Appl. WO2005044260, 2005.
40. Bonnert, R.; Rasul, R. (AstraZeneca) Novel substituted 3-sulfur indoles. PCT Int. Appl. WO2004106302, 2004.
41. Keegan, P.; Merifield, E.; Gill, D. (AstraZeneca) Novel process for the preparation of substituted indoles. PCT Int. Appl. WO2006075139, 2006.
42. Luker, T.; Bonnert, R.; Brough, S.; Cook, A. R.; Dickinson, M. R.; Dougall, I.; Logan, C.; Mohammed, R. T.; Paine, S.; Sanganee, H. J.; Sargent, C.; Schmidt, J. A.; Teague, S.; Thom, S. Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981 Bioorg. Med. Chem. Lett. 2011, 21, 6288-6292
43. 2) receptor antagonists for the treatment of allergic inflammatory diseases J. Med. Chem. 2008, 51, 2227-2243
44. 2) receptor antagonists ACS Med. Chem. Lett. 2011, 2, 644-649
45. Tumey, L. N.; Robarge, M. J.; Gleason, E.; Song, J.; Murphy, S. M.; Ekema, G.; Doucette, C.; Hanniford, D.; Palmer, M.; Pawlowski, G.; Danzig, J.; Loftus, M.; Hunady, K.; Sherf, B.; Mays, R. W.; Stricker-Krongrad, A.; Brunden, K. R.; Bennani, Y. L.; Harrington, J. J. 3-Indolyl sultams as selective CRTh2 antagonists Bioorg. Med. Chem. Lett. 2010, 20, 3287-3290
46. Bonnert, R. V.; Mohammed, R. T.; Teague, S. (AstraZeneca) 1-Acetic acid-indole, -indazole and -benzimidazole derivatives useful for the treatment of respiratory disorders. PCT Int. Appl. WO2005054232, 2005.
47. Sandham, D. A.; Adcock, C.; Bala, K.; Barker, L.; Brown, Z.; Dubois, G.; Budd, D.; Cox, B.; Fairhurst, R. A.; Furegati, M.; Leblanc, C.; Manini, J.; Profit, R.; Reilly, J.; Stringer, R.; Schmidt, A.; Turner, K. L.; Watson, S. J.; Willis, J.; Williams, G.; Wilson, C. 7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists Bioorg. Med. Chem. Lett. 2009, 19, 4794-4798
48. 2 at the CRTH2 receptor. GB Appl. GB2422830A, 2005.
49. 2). PCT Int. Appl. WO2005121141, 2005.
50. 2 at the CRTH2 receptor. GB Appl. GB2422829A, 2005.
51. 2 at the CRTH2 receptor. GB Appl. GB2422831a, 2005.
52. Hynd, G.; Montana, J. G.; Finch, H. (Argenta) Quinoline derivatives having DP and/or CRTH2 receptor activity. PCT Int. Appl., WO2010040992, 2010.
53. Bonafoux, D.; Abibi, A.; Bettencourt, B.; Burchat, A.; Ericsson, A.; Harris, C. M.; Kebede, T.; Morytko, M.; McPherson, M.; Wallace, G.; Wu, X. Thienopyrrole acetic acids as antagonists of the CRTH2 receptor Bioorg. Med. Chem. Lett. 2011, 21, 1861-1864
54. Ulven, T.; Receveur, J. M.; Grimstrup, M.; Rist, O.; Frimurer, T. M.; Gerlach, L. O.; Mathiesen, J. M.; Kostenis, E.; Uller, L.; Hogberg, T. Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits J. Med. Chem. 2006, 49, 6638-6641
55. Sandham, D. A.; Aldcroft, C.; Baettig, U.; Barker, L.; Beer, D.; Bhalay, G.; Brown, Z.; Dubois, G.; Budd, D.; Bidlake, L.; Campbell, E.; Cox, B.; Everatt, B.; Harrison, D.; Leblanc, C. J.; Manini, J.; Profit, R.; Stringer, R.; Thompson, K. S.; Turner, K. L.; Tweed, M. F.; Walker, C.; Watson, S. J.; Whitebread, S.; Willis, J.; Williams, G.; Wilson, C. 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists Bioorg. Med. Chem. Lett. 2007, 17, 4347-4350
56. Luker, T.; Bonnert, R.; Schmidt, J.; Sargent, C.; Paine, S. W.; Thom, S.; Pairaudeau, G.; Patel, A.; Mohammed, R.; Akam, E.; Dougall, I.; Davis, A. M.; Abbott, P.; Brough, S.; Millichip, I.; McInally, T. Switching between agonists and antagonists at CRTh2 in a series of highly potent and selective biaryl phenoxyacetic acids Bioorg. Med. Chem. Lett. 2011, 21, 3616-3621
57. Sargent, C.; Stinson, S.; Schmidt, J.; Dougall, I.; Bonnert, R.; Paine, S.; Saunders, M.; Foster, M. Br. J. Pharmacol. 2009, 98, pA2 online. See https://bps.conference-services.net/resources/344/1686/pdf/JB2009-0098.pdf.
58. Bonnert, R. V.; Luker, T. J.; Patel, A.; Rigby, A. (AstraZeneca) Novel compounds 951: A biphenyloxypropanoic acid as CRTH2 modulator and intermediates. PCT Int. Appl. WO2009004379, 2009.
59. Luker, T.; Bonnert, R.; Paine, S. W.; Schmidt, J.; Sargent, C.; Cook, A. R.; Cook, A.; Gardiner, P.; Hill, S.; Weyman-Jones, C.; Patel, A.; Thom, S.; Thorne, P. Zwitterionic CRTh2 antagonists J. Med. Chem. 2011, 54, 1779-1788
60. 2) receptor antagonists for the treatment of allergic inflammatory diseases J. Med. Chem. 2011, 54, 7299-7317
61. 2 receptors. US Appl. US20090197959, 2009.
62. 2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lung J. Pharmacol. Exp. Ther. 2010, 332, 764-775
63. 2 antagonists with efficacy in a murine model of allergic rhinitis Bioorg. Med. Chem. Lett. 2011, 21, 6608-6612
64. 2 receptor type 2 antagonist that is active in animal models of allergic inflammation J. Pharmacol. Exp. Ther. 2011, 338, 290-301
65. 2 antagonist and uses thereof. PCT Int. Appl. WO2011017201, 2011.
66. 2 receptors. PCT Int. Appl. WO2009102893, 2009.
67. Hutchinson, J. H.; Seiders, T. J.; Wang, B.; Arruda, J. M.; Stearns, B. A. (Amira) Antagonists of prostaglandin D2 receptors. PCT Int. Appl. WO2010003120, 2010.
68. 2 receptor antagonist Bioorg. Med. Chem. Lett. 2011, 21, 1036-1040
69. Doherty, G.; Cook, A. (Array BioPharma) 4-Substituted phenoxyphenylacetic acid derivatives. PCT Int. Appl. WO2008024746, 2008.
70. Bell, S.; Anderson, l.; Nugent, C.; Klopfenstein, N.; Carter, L.; Kass, C.; Rojas-Caro, S.; Burgess, L.; Bergstrom, B.; Miller S. Safety, PK and PD of ARRY-502, a CRTH2 antagonist, in healthy subjects with a history of seasonal allergies. Paper E3954 presented at the European Society Annual Congress, Barcelona, Spain, September 18 â̂ 22, 2010.
71. Liu, J.; Fu, Z.; Wang, Y.; Schmitt, M.; Huang, A.; Marshall, D.; Tonn, G.; Seitz, L.; Sullivan, T.; Lucy, T. H.; Collins, T.; Medina, J. Discovery and optimization of CRTH2 and DP dual antagonists Bioorg. Med. Chem. Lett. 2009, 19, 6419-6423
72. Liu, J.; Li, A.-R.; Wang, Y.; Johnson, M. G.; Su, Y.; Shen, W.; Wang, X.; Lively, S.; Brown, M.; Lai, S.; Lopez De Turiso, F. G.; Xu, Q.; Van Lengerich, B.; Schmitt, M.; Fu, Z.; Sun, Y.; Lawlis, S.; Seitz, L.; Danao, J.; Wait, J.; Ye, Q.; Tang, H. L.; Grillo, M.; Collins, T. L.; Sullivan, T. J.; Medina, J. C. Discovery of AMG 853, a CRTH2 and DP Dual Antagonist ACS Med. Chem. Lett. 2011, 2, 326-330
73. 1 antagonist laropiprant in asthma and allergic rhinitis J. Allergy Clin. Immunol. 2009, 124, 942-948
74. Liu, J.; Cheng, A. C.; Tang, H. L.; Medina, J. C. Benzodiazepinone Derivatives as CRTH2 Antagonists ACS Med. Chem. Lett. 2011, 2, 515-518
75. Rist, O.; Grimstrup, M.; Receveur, J. M.; Frimurer, T. M.; Ulven, T.; Kostenis, E.; Hogberg, T. Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 1 Bioorg. Med. Chem. Lett. 2010, 20, 1177-1180
76. Grimstrup, M.; Rist, O.; Receveur, J. M.; Frimurer, T. M.; Ulven, T.; Mathiesen, J. M.; Kostenis, E.; Hogberg, T. Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 2 Bioorg. Med. Chem. Lett. 2010, 20, 1181-1185
77. Grimstrup, M.; Receveur, J. M.; Rist, O.; Frimurer, T. M.; Nielsen, P. A.; Mathiesen, J. M.; Hogberg, T. Exploration of SAR features by modifications of thiazoleacetic acids as CRTH2 antagonists Bioorg. Med. Chem. Lett. 2010, 20, 1638-1641
78. Ly, T. W.; Li, H.-Y. (Actimis) Particulates of a CRTH2 antagonist. PCT Int. Appl. WO2008156780, 2008.
79. Ly, T. W. (Actimis) Amine salts of a CRTH2 antagonist. PCT Int. Appl. WO2008156781, 2008.
80. Boehme, S. A.; Franz-Bacon, K.; Chen, E. P.; Sasik, R.; Sprague, L. J.; Ly, T. W.; Hardiman, G.; Bacon, K. B. A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation Int. Immunol. 2009, 21, 81-93
81. Oost, T.; Anderskewitz, R.; Hamprecht, D. W.; Hoenke, C.; Martyres, D.; Rist, W.; Seither, P. (Boehringer Ingelheim) Pyrazole compounds as CRTH2 antagonists. PCT Int. Appl. WO2011092140, 2011.
82. Chen, L.; Firooznia, F.; Gillespie, P.; He, Y.; Lin, T.-A.; Mertz, E.; So, S.-S.; Yun, H.; Zhang, Z. (Roche) Naphthylacetic acids. PCT Int. Appl. WO20100055004, 2010.
83. Firooznia, F.; Gillespie, P.; Lin, T.-A.; Mertz, E.; Sidduri, A.; So, S.-S.; Jan, J.; Thakkar, K. C. (Roche) Naphthylacetic acids. PCT Int. Appl. WO2010055005, 2010.
84. Firooznia, F.; Lin, T.-A.; So, S.-S.; Wang, B.; Yun, H. (Roche) Naphthylacetic acids used as CRTH2 antagonists or partial agonists. PCT Int. Appl. WO2010055006, 2010.
85. Cramp, M. C.; Arienzo, R.; Hynd, G.; Crackett, P.; Griffon, Y.; Harrison, T. K.; Ray, N. C.; Finch, H.; Montana, J. G. (Argenta) Quinolines and their therapeutic use. PCT Int. Appl. WO2007036743, 2007.
86. Hynd, G.; Harris, N. V.; Bull, R. J.; Gardan, S.; Handa, B. K. (Argenta) 2-Oxo-2 H -chromene compounds. PCT Int. Appl. WO2007144625, 2007.
87. Montana, J. G.; Finch, H.; Hynd, G.; Cramp, M. C.; Arienzo, R.; Mclean, N. (Argenta) Quinolines and their therapeutic use. PCT Int. Appl. WO2008122784, 2008.
88. Ray, N. C.; Finch, H.; Cramp, M. C.; Arienzo, R.; Hynd, G.; Crackett, P.; Griffon, Y.; Harrison, T. K.; Trevor, K.; Montana, J. G. (Argenta) Quinoline derivatives as CRTH2 receptor ligands. PCT Int. Appl. WO2008119917, 2008.
89. Hynd, G.; Ray, N. C.; Finch, H.; Middlemiss, D.; Cramp, M. C.; Blaney, P. M.; Williams, K.; Griffon, Y.; Harrison, T. K.; Crackett, P. (Argenta) CRTH2 Antagonists. PCT Int. Appl. WO2008074966, 2008.
90. Hynd, G.; Montana, J. G.; Finch, H.; Cramp, M. C.; Ward, S. (Argenta) Quinolin-2-one compounds. PCT Int. Appl. WO2010040989, 2010.
91. Burgess, L. E.; Clark, C. T.; Cook, A.; Corrette, C. P.; Delisle, R. K.; Doherty, G. A.; Hunt, K. W.; Romoff, T. (Array Biopharma) 6-Substituted phenoxychroman carboxylic acid derivatives. PCT Int. Appl. WO2009158426, 2009.
92. Cook, A.; Hunt, K. W.; Delisle, R. K.; Romoff, T.; Clark, C. T.; Kim, G.; Corrette, C. P.; Doherty, G. A.; Burgess, L. E. (Array Biopharma) 7-Phenoxychroman carboxylic acid derivatives. PCT Int. Appl. WO2010075200, 2010.
93. Bonnert, R. V.; Luker, T. J.; Mohammed, R. T.; Thom, S.; Cook, A. (AstraZeneca) Novel compounds. PCT Int. Appl. WO2007068894, 2007.
94. 2 receptor antagonists for the treatment of inflammatory diseases. PCT Int. Appl. WO2004032848, 2004.
95. Awad, M. M. A.; Bazin, M.; Feru, F.; Goldstein, S. W.; Kuhn, C. F. (Warner-Lambert) Tetrahydroquinoline derivatives as CRTH2 antagonists. PCT Int. Appl. WO2004035543, 2004.
96. Mimura, H.; Ikemura, T.; Kotera, O.; Sawada, M.; Tashiro, S.; Fuse, E.; Ueno, K.; Manabe, H.; Ohshima, E.; Karasawa, A.; Miyaji, H. Inhibitory effect of the 4-aminotetrahydroquinoline derivatives, selective chemoattractant receptor-homologous molecule expressed on T helper 2 cell antagonists, on eosinophil migration induced by prostaglandin D2 J. Pharmacol. Exp. Ther. 2005, 314, 244-251
97. Liu, J.; Wang, Y.; Sun, Y.; Marshall, D.; Miao, S.; Tonn, G.; Anders, P.; Tocker, J.; Tang, H. L.; Medina, J. Tetrahydroquinoline derivatives as CRTH2 antagonists Bioorg. Med. Chem. Lett. 2009, 19, 6840-6844
98. 2 receptor antagonists for the treatment of inflammatory diseases. PCT Int. Appl. WO2006091674, 2006.
99. Page, P.; Schwarz, M.; Sebille, E.; Cleva, C.; Merlot, C.; Maio, M. (Merck Serono) 2,3-Substituted pyrazine sulfonamides as inhibitors of CRTH2. PCT Int. Appl. WO2006111560, 2006.
100. Hata, A. N.; Lybrand, T. P.; Marnett, L. J.; Breyer, R. M. Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2 Mol. Pharmacol. 2005, 67, 640-647
101. Hata, A. N.; Lybrand, T. P.; Breyer, R. M. Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2 J. Biol. Chem. 2005, 280, 32442-32451
102. Bailey, M.; Dickinson, R. G. Acyl glucuronide reactivity in perspective: Biological consequences Chem. Biol. Interact. 2003, 145, 117-137
103. Regan, S. L.; Maggs, J. L.; Hammond, T. G.; Lambert, C.; Williams, D. P.; Park, B. K. Acyl glucuronides: the good, the bad and the ugly Biopharm. Drug Dispos. 2010, 31, 367-395
104. Skonberg, C.; Olsen, J.; Madsen, K. G.; Hansen, S. H.; Grillo, M. P. Metabolic activation of carboxylic acids Expert Opin. Drug Metab. Toxicol. 2008, 4, 425-438
105. Grillo, M. P. Drug-S-acyl-glutathione thioesters: synthesis, bioanalytical properties, chemical reactivity, biological formation and degradation Curr. Drug Metab. 2011, 12, 229-244
106. Benet, L. Z.; Spahn-Langguth, H.; Iwakawa, S.; Volland, C.; Mizuma, T.; Mayer, S.; Mutschler, E.; Lin, E. T. Predictability of the covalent binding of acidic drugs in man Life Sci. 1993, 53, PL141-PL146
107. Baba, A.; Yoshioka, T. Structure-activity relationships for degradation reaction of 1-beta-o-acyl glucuronides: kinetic description and prediction of intrinsic electrophilic reactivity under physiological conditions Chem. Res. Toxicol. 2009, 22, 158-172
108. BoIcker, A.; Bonneau, P. R.; Hucke, O.; Jakalian, A.; Edwards, P. J. Development of specific drug-like property rules for carboxylate-containing oral drug candidates ChemMedChem 2010, 5, 2102-2113
109. Yazdanian, M.; Briggs, K.; Jankovsky, C.; Hawi, A. The high solubility definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs Pharm. Res. 2004, 21, 293-299
110. Smith, D. A.; Di, L; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: Misconceptions in drug discovery Nat. Rev. Drug Discovery 2010, 9, 929-939
111. Uetrecht, J. Prediction of a new drug's potential to cause idiosyncratic reactions Curr. Opin. Drug Discovery Dev. 2001, 4, 55-59
112. Uetrecht, J. Idiosyncratic drug reactions: past, present, and future Chem. Res. Toxicol. 2008, 21, 84-92
113. Zhu, B.-Y.; Jia, Z.; Zhang, P.; Ting, S.; Huang, W.; Goldman, E.; Tumas, D.; Kadambi, V.; Eddy, P.; Sinha, U.; Scarborough, R. M.; Song, Y. Inhibitory effect of carboxylic acid group on hERG binding Bioorg. Med. Chem. Lett. 2006, 21, 5507-5512
114. Waring, M. J.; Johnstone, C. A quantative assessment of hERG liability as a function of lipophilicity Bioorg. Med. Chem. Lett. 2007, 17, 1759-1764
115. Hunter, M. G; Pettipher, E. R.; Perkins, C. M.; Payton, M. A.; Xue, L. (Oxagen) Use of CRTH2 antagonist compounds. PCT Int. Appl. WO2009063215, 2009.
116. Haldar, P.; Brightling, C. E.; Hargadon, B.; Gupta, S.; Monteiro, W.; Sousa, A.; Marshall, R. P.; Bradding, P.; Green, R. H.; Wardlaw, A. J.; Pavord, I. D. Mepolizumab and exacerbations of refractory eosinophilic asthma N. Engl. J. Med. 2009, 360, 973-984
117. Castro, M.; Mathur, S.; Hargreave, F.; Boulet, L. P.; Xie, F.; Young, J.; Wilkins, H. J.; Henkel, T.; Nair, P. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 2011, 184, 1125-1132
118. Corren, J.; Lemanske, R. F.; Hanania, N. A.; Korenblat, P. E.; Parsey, M. V.; Arron, J. R.; Harris, J. M.; Scheerens, H.; Wu, L. C.; Su, Z.; Mosesova, S.; Eisner, M. D.; Bohen, S. P.; Matthews, J. G. Lebrikizumab treatment in adults with asthma N. Engl. J. Med. 2011, 365, 1088-1098